Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00059631 | Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone | completed | Phase 1 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00082732 | Behavior-Based Dietary Intervention in Treating Patients With Hormone-Refractory Prostate Cancer | completed | Phase 1 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT03237416 |
| Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers |
| completed |
| Phase 1 |
| 15 |
| BayerINDUSTRY |
| 1 |
| Nov 6, 2018 |
| clinicaltrials |
| NCT00038194 | Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer | completed | Phase 1 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00038246 | Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma | completed | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00379561 | PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer | completed | Phase 1 | 24 | Sophiris Bio CorpINDUSTRY | 1 | Oct 29, 2018 | clinicaltrials |
| NCT02234921 | Pilot Study of DRibble Vaccine for Prostate Cancer Patients(DRibble) | completed | Phase 1 | 3 | UbiVacINDUSTRY | 1 | Oct 11, 2018 | clinicaltrials |
| NCT01144897 | PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy | completed | Phase 1 | 5 | Daniel VaenaOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT01497925 | Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer | completed | Phase 1 | 43 | Polaris GroupINDUSTRY | 1 | Sep 13, 2018 | clinicaltrials |
| NCT01513733 | The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer(CATCH) | completed | Phase 1 | 25 | Andrew J. Armstrong, MDOTHER | 1 | Sep 4, 2018 | clinicaltrials |
| NCT01303705 | Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer | completed | Phase 1 | 13 | Providence Health & ServicesOTHER | 1 | Aug 29, 2018 | clinicaltrials |
| NCT01496157 | Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer | completed | Phase 1 / Phase 2 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT01815515 | Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 20, 2018 | clinicaltrials |
| NCT02297386 | [18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer | completed | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 6, 2018 | clinicaltrials |
| NCT01484015 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | completed | Phase 1 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01296139 | Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00804245 | C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer | completed | Phase 1 | 18 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT00892736 | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy | completed | Phase 1 | 98 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2018 | clinicaltrials |
| NCT00188513 | Intensity Modulated Radiation Therapy - Prostate Cancer | completed | Phase 1 / Phase 2 | 267 | University Health Network, TorontoOTHER | 1 | Jun 12, 2018 | clinicaltrials |
| NCT01385228 | Pazopanib, Docetaxel, Prednisone Prostate | completed | Phase 1 | 36 | Daniel George, MDOTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01129193 | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma | completed | Phase 1 | 44 | Amir MortazaviOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT01090765 | A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC) | completed | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | May 22, 2018 | clinicaltrials |
| NCT00822510 | Telephone Counseling: Men With Prostate Cancer & Partners | completed | Phase 1 | 79 | University of ArizonaOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT00061347 | Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Apr 23, 2018 | clinicaltrials |
| NCT02532114 | Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer | completed | Phase 1 | 5 | University of WashingtonOTHER | 1 | Apr 18, 2018 | clinicaltrials |
| NCT01567709 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 11, 2018 | clinicaltrials |
| NCT01934790 | Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases | completed | Phase 1 / Phase 2 | 45 | BayerINDUSTRY | 7 | Mar 26, 2018 | clinicaltrials |
| NCT01400555 | A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(mCRPC) | completed | Phase 1 | 22 | Cougar Biotechnology, Inc.INDUSTRY | 1 | Mar 21, 2018 | clinicaltrials |
| NCT01666314 | Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 137 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 20, 2018 | clinicaltrials |
| NCT02488070 | 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer | completed | Phase 1 / Phase 2 | 10 | Stanford UniversityOTHER | 1 | Mar 20, 2018 | clinicaltrials |
| NCT00878436 | Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration | completed | Phase 1 / Phase 2 | 52 | NYU Langone HealthOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT02363855 | Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects | completed | Phase 1 | 9 | BayerINDUSTRY | 1 | Jan 25, 2018 | clinicaltrials |
| NCT02014337 | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | completed | Phase 1 | 37 | Corcept TherapeuticsINDUSTRY | 1 | Jan 17, 2018 | clinicaltrials |
| NCT01949519 | Docetaxel and Lycopene in Metastatic Prostate Cancer | completed | Phase 1 | 24 | Medical University of South CarolinaOTHER | 1 | Jan 11, 2018 | clinicaltrials |
| NCT02514213 | Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer | completed | Phase 1 | 62 | Inovio PharmaceuticalsINDUSTRY | 1 | Dec 26, 2017 | clinicaltrials |
| NCT00620295 | Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors | completed | Phase 1 | 17 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00703638 | Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT01085422 | A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer | completed | Phase 1 | 35 | AbbVie (prior sponsor, Abbott)INDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT02705469 | A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 44 | Zenith EpigeneticsINDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT02916537 | A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057 | completed | Phase 1 | 20 | Cancer Targeted TechnologyINDUSTRY | 1 | Nov 6, 2017 | clinicaltrials |
| NCT00331344 | Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy | completed | Phase 1 / Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2017 | clinicaltrials |
| NCT00060528 | Sequential Vaccinations in Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Oct 26, 2017 | clinicaltrials |
| NCT02468284 | Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer | completed | Phase 1 | 15 | Ferring PharmaceuticalsINDUSTRY | 1 | Oct 26, 2017 | clinicaltrials |
| NCT01186484 | Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer | completed | Phase 1 | 27 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Oct 23, 2017 | clinicaltrials |
| NCT02911350 | Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer | completed | Phase 1 | 23 | NYU Langone HealthOTHER | 0 | Oct 2, 2017 | clinicaltrials |
| NCT01254578 | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2017 | clinicaltrials |
| NCT02654938 | Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer | completed | Phase 1 | 32 | Panacela Labs LLCINDUSTRY | 1 | Sep 20, 2017 | clinicaltrials |
| NCT02280811 | T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Sep 6, 2017 | clinicaltrials |
| NCT01832870 | Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer | completed | Phase 1 | 9 | Prostate Oncology Specialists, Inc.OTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00958477 | A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer | completed | Phase 1 | 26 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 2 | Aug 2, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Nov 15, 2018source: clinicaltrials